wherein:

R^1 is aryl;

R^2 is H, alkyl or aryl; and

R^3 is hydrogen or alkyl;

or a pharmaceutically acceptable salt or prodrug thereof.

2. (Amended) A method according to claim 1, wherein R^1 is a substituted or unsubstituted phenyl or naphthyl.

3. (Amended) A method according to claim 1, wherein R^1 has 1, 2 or 3 substituent groups.

Cl cont.

4. (Amended) A method according to claim 1, wherein R^1 is chlorophenyl, fluorophenyl, (trifluoromethyl)phenyl, 3, 4-dichlorophenyl or 3, 4-difluorophenyl.

5. (Amended) A method according to claim 1, wherein R^2 is hydrogen or methyl.

6. (Amended) A method according to claim 1, wherein R^3 is alkyl.

7. (Amended) A method according to claim 1, wherein R^3 is alkenyl, alkynyl, hydroxyalkyl or alkoxyalkyl.

8. (Amended) A method according to claim 1, wherein R^3 is allyl or propargyl.

9. (Amended) A method according to claim 1, wherein R^3 is unsubstituted saturated cyclic or acyclic hydrocarbyl.

10. (Amended) A method according to claim 1 wherein the compound is selected from:

3-(4-chlorobenzyloxy)-N-(2-propenyl) azetidine-1-carboxamide,

3-(3,4-dichlorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(3-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(4-(trifluoromethyl)benzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(4-fluorobenzyloxy)-N-(2-propenyl)azetidine-1-carboxamide,

3-(bis(4-chlorophenyl)methoxy)-N-(2-propenyl)azetidine-1-carboxamide,

(R)-3-(bis(4-chlorophenyl)methoxy)-N-(2-hydroxypropyl)azetidine-1-carboxamide,

3-((3-chlorophenyl) methoxy)-azetidine-1-carboxamide, and

3-(1-(3-trifluoromethylphenyl)ethyloxy)-azetidine-1-carboxamide.

Cl cont.

11. (Amended) A method according to claim 1, wherein said compound is in combination with a pharmaceutically acceptable carrier.

12. (Amended) A method according to claim 11, wherein said carrier comprises a cyclodextrin or an ether derivative thereof.

13. (Amended) A method according to claim 11, wherein said carrier further comprises a buffer system, an isotonizing agent and water.

14. (Amended) A method according to claim 1, wherein the compound of formula (I) is in combination with one or more additional drugs useful in neuroprotection or in the treatment of cerebral ischaemia, central nervous system injury or eye diseases, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.